ClinicalTrials.gg
RecruitingNCT07295522PopS-HFUpdated Oct 16, 2026

Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?

A Phase 4 interventional study of Guideline-Directed Medical Therapy (GDMT) in Heart Failure, Acute Heart Failure and Heart Failure With Reduced Ejection Fraction (HFrEF), sponsored by IRCCS Policlinico S. Donato. Recruiting at 12 sites in Italy. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by IRCCS Policlinico S. Donato · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 16, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
368
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 449 studies in Heart Failure with a site in Italy — 110 open to participants now, 130 under way, 18 of them phase 3. Heart Failure · Italy.

Planned enrollment
113th of 292
368 · median 200
Started
2026
with 22 others
Phase 4
36 of 449
3 open now
Primary completion
2027-06
later than 72 of 129 live
Registered
421st of 449
by date

Among the 449 studies in Heart Failure with a site in Italy, this one is the 113th largest by planned enrollment of the 292 interventional ones that give a count, is one of 23 that started in 2026, is one of 36 in phase 4, reaches primary completion later than 72 of the 129 other live ones, and was the 421st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

110 of the 449 studies in Heart Failure with a site in Italy are open now. Recruiting first, the newest first:

104 more — sign in →

All 110 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 449 studies in Heart Failure with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether a rapid and intensive optimization of heart failure medications in women can improve outcomes after hospitalization for heart failure. It will also investigate the safety and the tolerance of these treatments when given at full guideline-recommended doses.

The main questions it aims to answer are:

  1. Does intensive medication optimization reduce death or hospital readmissions for heart failure within one year?
  2. Do women benefit as much as men from intensive and full-dose heart failure therapy?
  3. Is this treatment protocol safe and feasible also in women?

Researchers will compare two groups of women hospitalized for heart failure:

  • High-intensity care: starting and increasing all recommended heart-failure medications as quickly as possible and monitoring patients closely during the first weeks after discharge.
  • Usual care: medications are started and adjusted gradually, according to the judgment of the treating cardiologist and the patient's usual care team.

The study will follow participants for 12 months to see whether the high-intensity strategy reduces death, hospital readmission for heart failure, or worsening symptoms. It will also evaluate side effects, medication tolerance, and quality of life.

Participants will be randomly assigned to one of the two groups, attend regular follow-up visits for one year, complete a short quality-of-life questionnaire (EQ-5D).

This study will include about 360 women from 13 hospitals in Italy. It is sponsored by IRCCS Policlinico San Donato and funded by the Italian Medicines Agency (AIFA).

Read the detailed description

PopS-HF is a phase IV, low-interventional, multicenter randomized controlled trial designed to test whether intensive optimization of guideline directed medical therapy (GDMT), following the STRONG-HF (Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing of Heart Failure Therapies) titration strategy, improves outcomes in women hospitalized for heart failure (HF).

The study also includes a retrospective analysis of national healthcare databases and specialized HF registries from 2018-2023 to evaluate how GDMT are prescribed in real-world practice and to identify sex-related differences in treatment patterns and outcomes.

Eligible patients are women aged 18-85 years hospitalized for acute HF with evidence of congestion and hemodynamic stability before discharge. Exclusion criteria include severe comorbidities, pregnancy, and inability to follow up.

The prospective component randomizes 368 patients to an intensive strategy or usual care, with follow-up visits at 2, 4, 6, 12, 24, 36, and 52 weeks.

The primary endpoint is a composite of all-cause mortality, HF readmission, or worsening HF within 1 year.

Secondary endpoints assess optimization of therapy, side effects, biomarkers (NT-proBNP), and quality of life.

03

Conditions studied

  • Heart Failure
  • Acute Heart Failure
  • Heart Failure With Reduced Ejection Fraction (HFrEF)
  • Heart Failure With Preserved Ejection Fraction (HFPEF)
  • Heart Failure With Mildly Reduced Ejection Fraction

Browse trials for

Keywords

  • heart failure
  • women
  • GDMT
  • Pharmacological Optimization
  • phase IV
  • High intensity up-titration
  • Secondary prevention
  • Sex differences
  • Real world data
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients >18 \<85 years.
  2. Hospital admission within the 72 hours prior to Screening for acute heart failure with dyspnea at rest and pulmonary congestion on chest X-ray, and other signs and/or symptoms of heart failure such as edema and/or positive rales on auscultation.
  3. All measures within 24 hours prior to Randomization of systolic blood pressure ≥ 100 mmHg, and of heart rate ≥ 60 bpm.
  4. All measures within 24 hours prior to Randomization of serum potassium ≤ 5.0 mEq/L (mmol/L).
  5. Biomarker criteria for persistent congestion:

    5.1. At Screening, NT-proBNP >1,800 pg/mL (2,350 pg/mL in case of atrial fibrillation) 5.2. At the time of Randomization (1-2 days prior to discharge), NT-proBNP >1,000 pg/mL (1,300 pg/mL in case of Atrial Fibrillation) to ensure the persistence of congestion and the acuity of the index episode).

  6. At 1 week prior to admission, at Screening, and at Visit 2 6.1. If EF\<50% (ie HFrEF or HFmrEF) either \<½ the optimal dose of ACEi/ARB/ARNi and MRA and BB or no SGLT2i (see Table) must have been prescribed 6.2. If EF>50% (ie HFpEF): \<½ the optimal dose of MRA (see Table) or no SGLT2i.
  7. Written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Male patients
  2. Age \< 18 or > 85 years.
  3. Mechanical ventilation (not including CPAP/BIPAP) in the 24 hours prior to Screening.
  4. Significant pulmonary disease contributing substantially to the patients' dyspnoea such as \<1 liter or need for chronic systemic or nonsystemic therapy, or any kind of primary right heart failure such as primary pulmonary hypertension or recurrent pulmonary embolism.
  5. Myocardial infarction, unstable angina or cardiac surgery within 3 months, or cardiac resynchronization therapy (CRT) device implantation within 3 months, or percutaneous transluminal coronary intervention (PTCI), within 1 month prior to Screening or during the index event.
  6. Index Event (admission for Acute Heart Failure) triggered primarily by a correctable aetiology such as significant arrhythmia (e.g., sustained ventricular tachycardia, or atrial fibrillation/flutter with sustained ventricular response >130 beats per minute, or bradycardia with sustained ventricular arrhythmia \<45 beats per minute), infection, severe anaemia, acute coronary syndrome, pulmonary embolism, exacerbation of (COPD), planned admission for device implantation or severe non-adherence leading to very significant fluid accumulation prior to admission and brisk diuresis after admission. Troponin elevations without other evidence of an acute coronary syndrome are not an exclusion.
  7. Uncorrected thyroid disease, active myocarditis, or known amyloid or hypertrophic obstructive cardiomyopathy.
  8. History of heart transplant or on a transplant list or using or planned to be implanted with a ventricular assist device.
  9. Sustained ventricular arrhythmia with syncopal episodes within the 3 months prior to screening that is untreated.
  10. Presence at Screening of any hemodynamically significant valvular stenosis or regurgitation, except mitral or tricuspid regurgitation secondary to left ventricular dilatation, or the presence of any hemodynamically significant obstructive lesion
  11. Active infection at any time during the AHF hospitalization prior to Randomization based on abnormal temperature and elevated WBC or need for intravenous antibiotics.
  12. Stroke or (TIA) within the 3 months prior to Screening.
  13. Primary liver disease considered to be life threatening.
  14. Renal disease or \< 30 mL/min/1.73m2 (as estimated by the simplified MDRD formula) at Screening or history of dialysis.
  15. Psychiatric or neurological disorder, cirrhosis, or active leading to a \< 6 months.
  16. Prior (defined as less than 30 days from screening) or current enrollment in a CHF trial or participation in an drug or device study within the 30 days prior to screening or 5 half-lives of the study drug, whichever is longer.
  17. Discharge for the AHF hospitalization anticipated to be >14 days from admission, or to a long-term care facility. Randomization must occur within 12 days following admission and at 1-2 days prior to anticipated discharge.
  18. Inability to comply with all study requirements, due to major co-morbidities, social or financial issues or a history of noncompliance with medical regimens, that might compromise the patient's ability to understand and/or comply with the protocol instructions or follow-up procedures.
  19. Pregnant or nursing (lactating) women.
  20. to the active substance or to any of the as indicated in Summary of Product Characteristics of Investigational Medicinal Product (IMPs).
  21. Angioedema.
  22. Severe heart failure ( class IV).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
368 participants (estimated)

Study arms

  • No intervention
    Usual care

    Participants in the usual care arm will receive sequential introduction and adjustment of guideline-directed medical therapy (GDMT) according to the treating cardiologist or general physician's clinical judgment, following routine practice. Follow-up will occur at weeks 6, 12, 24, 36, and 52 after randomization, with clinical visits and intermediate phone contacts as per standard care.

  • Experimental
    High-intensity care

    Participants assigned to the high-intensity arm will begin rapid initiation and optimization of guideline-directed medical therapy (GDMT) according to the STRONG-HF protocol. During hospitalization, eligible therapies (beta-blockers (BB), Angiotensin converting enzyme inhibitor(ACEi) /Angiotensin II receptor blocker (ARB)/Angiotensin Receptor-Neprilysin Inhibitors(ARNI), Mineralocorticoid Receptor Antagonists (MRA), and Sodium-Glucose Co-Transporter inhibitor 2 (SGLT2i) for HFrEF/HFmrEF; MRA and SGLT2i for HFpEF will be prescribed at least at half of the recommended target dose. Further titration toward full optimal doses will be performed within the first 6 weeks if clinically appropriate. Participants will undergo clinical assessments at weeks 2, 4, 6, 12, 24, 36, and 52, with safety monitoring including vital signs, physical examination, and laboratory evaluation (NT-proBNP, electrolytes, kidney function). Additional visits may occur after any up-titration if needed for safety.

    Drug: Guideline-Directed Medical Therapy (GDMT)

Interventions

  • DrugGuideline-Directed Medical Therapy (GDMT)

    Guideline-directed medical therapy (GDMT) including beta-blockers, ACE inhibitors or ARBs or ARNIs, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, all approved and commercially available, used according to current ESC guidelines. Participants in the high-intensity care arm are assigned to a strategy of rapid initiation and optimization of GDMT based on the STRONG-HF protocol. Eligible therapies (beta-blockers, ACEi/ARB/ARNI, mineralocorticoid receptor antagonists, and SGLT2 inhibitors for HFrEF/HFmrEF; MRA and SGLT2 inhibitors for HFpEF) are started during hospitalization at least at half of the recommended target dose, followed by frequent clinical assessments and dose titration, when clinically appropriate, within 6 weeks. Safety monitoring includes clinical examination, vital signs, laboratory tests (NT-proBNP, electrolytes, kidney function), and additional visits after each titration if needed.

06

What researchers measure

Primary outcomes

  1. Composite of all-cause mortality, heart failure (HF) readmission, or worsening HF within 1 year.

    Composite endpoint including occurrence of (1) death from any cause, (2) hospital readmission for heart failure, or (3) clinically assessed worsening of heart failure.

    Time frame: 12 months

Secondary outcomes

  1. Optimization of Beta-blocker Therapy

    Percentage of participants achieving dose optimization of beta-blockers according to guideline-recommended targets or maximum tolerated dose.

    Time frame: 12 months

  2. Optimization of ACEi/ARB/ARNI Therapy

    Proportion of participants achieving dose optimization of ACE inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin inhibitors according to guideline-recommended targets or maximum tolerated dose.

    Time frame: 12 months

  3. Optimization of Mineralocorticoid Receptor Antagonists (MRAs)

    percentage of participants achieving dose optimization of MRAs at recommended dose or maximum tolerated dose.

    Time frame: 12 months

  4. Optimization of SGLT2 Inhibitors

    Percentage of poulation achieving full implementation of SGLT2 inhibitors

    Time frame: 12 months

  5. Discontinuation of GDMT due to side effects

    Percentage of participants discontinuing any GDMT class (beta-blockers, ACEi/ARB/ARNI for EF \<50%, MRAs, or SGLT2 inhibitors) due to adverse effects or intolerance.

    Time frame: 12 months

  6. NT-proBNP Changes

    Change in plasma NT-proBNP levels from baseline to follow-up visits in each study arm.

    Time frame: 12 months

  7. Quality of Life (EQ-5D-5L Score)

    Change in health-related quality of life measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The EQ-5D-5L also includes a visual analogue scale (VAS) ranging from 0 to 100, with higher scores indicating better perceived health status.

    Time frame: 12 months

  8. One-year All-Cause Mortality

    Incidence of death from any cause within 12 months after randomization.

    Time frame: 12 months

  9. One-year Heart Failure Readmission

    Incidence of hospital readmission for heart failure within 12 months after randomization.

    Time frame: 12 months

  10. One-year Worsening Heart Failure

    Incidence of worsening heart failure within 12 months after randomization, defined as deterioration of heart failure signs and symptoms requiring urgent escalation of therapy, including emergency department visit or outpatient intravenous diuretic therapy.

    Time frame: 12 months

Other outcomes

  1. Proportion of participants experiencing the composite endpoint of all-cause mortality, heart failure hospitalization, or worsening heart failure at 12 months

    Proportion of participants experiencing at least one of the following events within 12 months: all-cause mortality, hospitalization for heart failure, or worsening heart failure. Worsening heart failure is defined as deterioration of heart failure signs and symptoms in a patient with chronic heart failure despite previously stable background therapy, requiring urgent escalation of therapy, including emergency department visit or outpatient intravenous diuretic therapy, with or without intensification of oral therapy. The composite endpoint is defined as the occurrence of any of the above events within 12 months. Results will be reported as the proportion of participants with ≥1 event in the following pre-specified subgroups: * Heart failure phenotype: HFrEF and HFmrEF versus HFpEF * Age: \<65 years versus ≥65 years * Patients with Diabetes mellitus * patients with Chronic kidney disease * patients with obesity

    Time frame: 12 months

07

Study locations

1 of 12 sites recruiting
08

References and documents

Publications

  • Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees*. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016 Jun 7;133(23):2254-62. doi: 10.1161/CIRCULATIONAHA.115.020729. Epub 2016 Apr 20. PubMed 27143684 ↗
  • Brotons C, Falces C, Alegre J, Ballarin E, Casanovas J, Cata T, Martinez M, Moral I, Ortiz J, Perez E, Rayo E, Recio J, Roig E, Vidal X. Randomized clinical trial of the effectiveness of a home-based intervention in patients with heart failure: the IC-DOM study. Rev Esp Cardiol. 2009 Apr;62(4):400-8. doi: 10.1016/s1885-5857(09)71667-6. English, Spanish. PubMed 19401125 ↗
  • Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M, Takagi K, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022 Dec 3;400(10367):1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7. PubMed 36356631 ↗
  • Dewan P, Rorth R, Jhund PS, Shen L, Raparelli V, Petrie MC, Abraham WT, Desai AS, Dickstein K, Kober L, Mogensen UM, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. J Am Coll Cardiol. 2019 Jan 8;73(1):29-40. doi: 10.1016/j.jacc.2018.09.081. PubMed 30621948 ↗
  • Lainscak M, Milinkovic I, Polovina M, Crespo-Leiro MG, Lund LH, Anker SD, Laroche C, Ferrari R, Coats AJS, McDonagh T, Filippatos G, Maggioni AP, Piepoli MF, Rosano GMC, Ruschitzka F, Simic D, Asanin M, Eicher JC, Yilmaz MB, Seferovic PM; European Society of Cardiology Heart Failure Long-Term Registry Investigators Group. Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2020 Jan;22(1):92-102. doi: 10.1002/ejhf.1645. Epub 2019 Dec 20. PubMed 31863522 ↗
  • Butler J, Yang M, Sawhney B, Chakladar S, Yang L, Djatche LM. Treatment patterns and clinical outcomes among patients <65 years with a worsening heart failure event. Eur J Heart Fail. 2021 Aug;23(8):1334-1342. doi: 10.1002/ejhf.2252. Epub 2021 Jun 17. PubMed 34053163 ↗
  • Fiuzat M, Ezekowitz J, Alemayehu W, Westerhout CM, Sbolli M, Cani D, Whellan DJ, Ahmad T, Adams K, Pina IL, Patel CB, Anstrom KJ, Cooper LS, Mark D, Leifer ES, Felker GM, Januzzi JL, O'Connor CM. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2020 Jul 1;5(7):757-764. doi: 10.1001/jamacardio.2020.0640. PubMed 32319999 ↗
  • Kapelios CJ, Murrow JR, Nuhrenberg TG, Montoro Lopez MN. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev. 2019 May;24(3):367-377. doi: 10.1007/s10741-018-9758-0. PubMed 30618017 ↗
  • Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1. PubMed 35363499 ↗
  • Najafi F, Jamrozik K, Dobson AJ. Understanding the 'epidemic of heart failure': a systematic review of trends in determinants of heart failure. Eur J Heart Fail. 2009 May;11(5):472-9. doi: 10.1093/eurjhf/hfp029. Epub 2009 Feb 27. PubMed 19251729 ↗
  • Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Bohm M, Butler J, Carapetis J, Ceconi C, Chioncel O, Coats A, Crespo-Leiro MG, de Simone G, Drexel H, Emdin M, Farmakis D, Halle M, Heymans S, Jaarsma T, Jankowska E, Lainscak M, Lam CSP, Lochen ML, Lopatin Y, Maggioni A, Matrone B, Metra M, Noonan K, Pina I, Prescott E, Rosano G, Seferovic PM, Sliwa K, Stewart S, Uijl A, Vaartjes I, Vermeulen R, Verschuren WM, Volterrani M, Von Haehling S, Hoes A. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2022 Feb 19;29(1):275-300. doi: 10.1093/eurjpc/zwab147. PubMed 35083485 ↗
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available. PubMed 34447992 ↗

Individual participant data

Plan to share: No — De-identified individual participant data (IPD) will not be made publicly available. Data sharing is restricted due to ethical and regulatory requirements under GDPR and Italian data protection regulations. Aggregate study results will be published.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 14 months is below that.

Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Mar 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 19, 2025
StartActual
Mar 31, 2026was Apr 2026
Primary completionEst.
Jun 8, 2027
CompletionEst.
Jun 8, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
1 site removed. 12 sites changed recruiting status (11 now not yet recruiting, 1 now recruiting)
Show 12 sites
  • IRCCS Policlinico San Donato · San Donato Milanese, Italyno status→Recruiting
  • Azienda Ospedaliero Universitaria Delle Marche · Ancona, Italyno status→Not yet recruiting
  • Azienda USL Toscana Nord Ovest - Cecina · Cecina, Italyno status→Not yet recruiting
  • Ospedale Universitario di Ferrara · Ferrara, Italyno status→Not yet recruiting
  • Azienda USL Toscana Centro · Florence, Italyno status→Not yet recruiting
  • Centro Cardiologico Monzino · Milan, Italyno status→Not yet recruiting
  • Istituto Auxologico Italiano · Milan, Italyno status→Not yet recruiting
  • Fondazione Toscana Gabriele Monasterio · Pisa, Italyno status→Not yet recruiting
  • Ospedale S. Maria delle Croci · Ravenna, Italyno status→Not yet recruiting
  • Azienda USL IRCCS Di Reggio Emilia · Reggio Emilia, Italyno status→Not yet recruiting
  • Fondazione Policlinico Universitario Campus Bio-medico · Roma, Italyno status→Not yet recruiting
  • Ospedale San Camillo Forlanini · Roma, Italyno status→Not yet recruiting
Show 1 removed
  • Azienda Sanitaria Locale Bari · Bari, Italy
Oct 16, 2026
Start date
Apr 8, 2026→Mar 31, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    1 site removed. 12 sites changed recruiting status (11 now not yet recruiting, 1 now recruiting)
    Show 12 sites
    • IRCCS Policlinico San Donato · San Donato Milanese, Italyno status→Recruiting
    • Azienda Ospedaliero Universitaria Delle Marche · Ancona, Italyno status→Not yet recruiting
    • Azienda USL Toscana Nord Ovest - Cecina · Cecina, Italyno status→Not yet recruiting
    • Ospedale Universitario di Ferrara · Ferrara, Italyno status→Not yet recruiting
    • Azienda USL Toscana Centro · Florence, Italyno status→Not yet recruiting
    • Centro Cardiologico Monzino · Milan, Italyno status→Not yet recruiting
    • Istituto Auxologico Italiano · Milan, Italyno status→Not yet recruiting
    • Fondazione Toscana Gabriele Monasterio · Pisa, Italyno status→Not yet recruiting
    • Ospedale S. Maria delle Croci · Ravenna, Italyno status→Not yet recruiting
    • Azienda USL IRCCS Di Reggio Emilia · Reggio Emilia, Italyno status→Not yet recruiting
    • Fondazione Policlinico Universitario Campus Bio-medico · Roma, Italyno status→Not yet recruiting
    • Ospedale San Camillo Forlanini · Roma, Italyno status→Not yet recruiting
    Show 1 removed
    • Azienda Sanitaria Locale Bari · Bari, Italy
    Start date Apr 8, 2026→Mar 31, 2026 (now actual)
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07295522
Collaborators
Agenzia Italiana del Farmaco
Responsible party
Massimo Piepoli (Professor, IRCCS Policlinico S. Donato) — Principal investigator
First posted
Dec 19, 2025
Start date
Mar 31, 2026
Primary completion
Jun 8, 2027 (estimated)
Completion
Jun 8, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Massimo Piepoli, MD
Contact
MASSIMO.PIEPOLI@GRUPPOSANDONATO.IT
0252774966
Giovanna Landi, PharmD
Contact
GIOVANNA.LANDI@GRUPPOSANDONATO.IT
0252774885

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion